

## Health And Youth Care Inspectorate

CERTIFICATE NUMBER: *NL/H 22/2039369A*

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER<sup>1,2</sup>

### Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: **Medcor Pharmaceuticals B.V.**

Site address: **Artemisweg 232, Lelystad, 8239 DE, Netherlands**

OMS Organisation Id. / OMS Location Id.: **ORG-100013485 / LOC-100019037**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **4491 F** in accordance with Art. 40 of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2022-11-16**, it is considered that it complies with:

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2.<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (<http://eudragmdp.ema.europa.eu/>). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

<sup>1</sup>The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC is also applicable to importers.

<sup>2</sup>Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

<sup>3</sup>These requirements fulfil the GMP recommendations of WHO.

## Part 2

Human Medicinal Products	
<b>1 MANUFACTURING OPERATIONS</b>	
<b>1.1</b>	<b>Sterile products</b>
	<i>1.1.3 Batch certification</i>
<b>1.2</b>	<b>Non-sterile products</b>
	<i>1.2.2 Batch certification</i>
<b>1.3</b>	<b>Biological medicinal products (list of product types)</b>
	<i>1.3.2 Batch Certification (list of product types)</i> 1.3.2.1 Blood products 1.3.2.2 Immunological products 1.3.2.5 Biotechnology products
<b>1.5</b>	<b>Packaging</b>
	<i>1.5.2 Secondary packaging</i>

Clarifying remarks (for public users)

***Batch certification activities (items 1.1.3, 1.2.2, 1.3.2.1, 1.3.2.2 and 1.3.2.5) only refer to batch certification after secondary packing (item 1.5.2)***

2023-05-10

Name and signature of the authorised person of the  
Competent Authority of Netherlands

-----  
**Confidential**  
**Health And Youth Care Inspectorate**  
Tel: **Confidential**  
Fax: **Confidential**

## Health And Youth Care Inspectorate

CERTIFICATE NUMBER: **NL/H 22/2039369B**

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER<sup>1,2</sup>

### Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: **Medcor Pharmaceuticals B.V.**

Site address: **Schutweg 23, Lelystad, 8243 PC, Netherlands**

OMS Organisation Id. / OMS Location Id.: **ORG-100013485 / LOC-100051066**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **4491 F** in accordance with Art. 40 of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2022-11-16**, it is considered that it complies with:

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2.<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (<http://eudragmdp.ema.europa.eu/>). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

<sup>1</sup>The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC is also applicable to importers.

<sup>2</sup>Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

<sup>3</sup>These requirements fulfil the GMP recommendations of WHO.

**Part 2**

Human Medicinal Products	
<b>1 MANUFACTURING OPERATIONS</b>	
<b>1.5</b>	<b>Packaging</b>
	<i>1.5.2 Secondary packaging</i>

**2023-05-10**

Name and signature of the authorised person of the  
Competent Authority of Netherlands

-----  
*Confidential*  
*Health And Youth Care Inspectorate*  
Tel: *Confidential*  
Fax: *Confidential*